| We currently have two preclinical research pipeline
programs focused on antiplatelet therapy and cancer. Platelets
serve the cause of hemostasis by adhering to and spreading over
subendothelial surfaces, aggregating to each other and supplying
a substrate for blood plasma coagulation reactions leading to
fibrin formation. Platelet-fibrin plug formation, crucial to
normal hemostasis and prevention of bleeding, becomes pathological
and leads to thrombosis when pro-aggregatory and prothrombotic
processes are excessive or inappropriate.
Widespread adoption of the antiplatelet agents into everyday
clinical practice has revolutionized contemporary care of
cardiovascular patients. Currently three types of antiplatelet
agents are used for clinical purposes: aspirin, thienopyridines
and GP IIb/IIIa receptor inhibitors. HuMA is currently evaluating
the therapeutic potential of novel compounds in the GP IIb/IIIa
receptor inhibitor class. Our objective is to advance these
antibody therapeutics for the treatment of patients with acute
coronary syndrome and other associated indications. |
Home
